Publications

cemka > Publications

Sort publications on year

  • Biometry and database analysis

    Comorbidities in people living with HIV: An epidemiologic and economic analysis using a claims database in France

    POURCHER V, GOURMELEN J, BUREAU I, BOUEE S

    PLOS ONE ; 2020;15(12),e0243529

  • Pharmaco - Epidemiology

    Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation

    HANON O, VIDAL JS, PISICA-DONOSE G, ORVOËN G, DAVID JP, CHAUSSADE E, CAILLARD L, DE JONG LW, BOULLOCHE N, VINSONNEAU U, BOUEE S, KROLAK-SALMON P, FAUCHIER L, JOUANNY P, SACCO G, BELLARBRE F, BELMIN J, PUISIEUX F, LILAMAND M, PAILLAUD E, BOUREAU AS ; SAFIR STUDY GROUP

    Heart ; 2020(Online)

  • Pharmaco - Epidemiology

    Three-year clinical outcomes in patients with rheumatoid arthritis treated with certolizumab pegol: results from the observational ECLAIR study.

    SARAUX A, COMBE B, FAGNANI F, CUKIERMAN G, BRU I, JOUBERT J.-M , SCHULLER J.-C, MASSOL J, FLIPO R.-M

    Clinical and Experimental Rheumatology ; 2020(Online)

  • Pharmaco-Economics

    Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti-FVIII inhibitors in France.

    POLACK B, TROSSAËRT M, COUSIN M, BAFFERT S, PRUVOT A, GODARD C.

    Haemophilia ; 2020;27(1)e1-e11

  • Public Health and Epidemiology

    Expérimentation de la télé-expertise en cardiologie en Pays de la Loire.

    HERAULT T, DONIO V, COUROUVE L, CAILLARD J.-B.

    Santé publique ; 2019;31(6):789-796

  • Biometry and database analysis

    Cost of Managing Type 2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database

    EMERY C, TORRETON E, DEJAGER S, LEVY-BACHELOT L, BINEAU S, DETOURNAY B.

    Diabetes Ther ; 2020;11(2):535-548

  • Public Health and Epidemiology

    Evaluation en éducation thérapeutique.

    SIMON D, DETOURNAY B.

    Education Thérapeutique. Prévention et maladies chroniques Issy les Moulineaux, Elsevier Masson Ed. Collection Abrégés 4ème édition revue et augmentée ; 2020;407-420

  • Biometry and database analysis

    Profile of Women Initiated on Denosumab and Pattern of Use in a Restricted Postmenopausal Osteoporosis Indication: A French Database Analysis Over the Period 2013-2014.

    EMERY C, GOURMELEN J, FAGNANI F, SUZAN F, DESAMERICQ G, FARDELLONE P.

    Adv Ther ; 2019;36(4),969-975

  • Public Health and Epidemiology

    Prise en charge précoce des psychoses émergentes en France. Recensement, description des activités et besoins en 2018.

    LECARDEUR L, MEUNIER-CUSSAC S, GOZLAN G, DUBURCQ A, COUROUVE L, KREBS M-O.

    L’Information psychiatrique ; 2020;96(7),569-576

  • Pharmaco - Epidemiology

    Mepolizumab in a population with severe osinophilic asthma and corticosteroid dependence: results from French early access programme

    TAILLE C, CHANEZ P, DEVOUASSOUX G, DIDIER A, PISON C, GARCIA G, CHARRIOT J, BOUEE S, GRUBER A, PRIBIL C, BOURDIN A, HUMBERT M.

    Eur Respir J ; 2020;55(6)

  • Pharmaco - Epidemiology

    Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study

    GIRARD N, MORO-SIBILOT D, BOUEE S, EMERY C, TORRETON E, LE LAY K, LUCIANI L, MARITAZ C, CHOUAID C.

    Future Oncol ; 2020;16(16),1115-1124

  • Biometry and database analysis

    Economic burden of coronary artery disease or peripheral artery disease in patients at high risk of ischemic events in the French setting: a claims database analysis.

    EMERY C, TORRETON E, BRIERE JB, THOMAS EVERS T, FAGNANI F.

    J Med Econ ; 2020;23(5):513-520

  • OthersPublic Health and Epidemiology

    The management of emergency hospital visits for inflammatorybowel diseases: A French national expert consensus report

    HEBUTERNE X, PEYRIN-BIROULET L, HAUSFATER P.

    Therapie ; 2020;52(4),420-426

  • Others

    Télésurveillance et expérimentations ETAPES. Quelle pérennité après 2021 : quel modèle organisationnel et financement ?

    LE DOUARIN Y, TRAVERSINO Y, GRACIET A, JOSSERAN A, ET LES PARTICIPANTS DE LA TABLE RONDE « SANTE ET ECONOMIE » DES ATELIERS DE GIENS XXXV, BRIAC BILI A, BLAISE L, CHATELLIER G, COULONJOU H, DELVAL C, DETOURNAY B, DURAND ZALESKI I, FOREST J, DAIDANI N, VANDENBERGUE J.

    Therapies ; 2020;75(1),29-42

  • Public Health and Epidemiology

    The management of emergency hospital visits for inflammatorybowel diseases: A French national expert consensus report.

    HEBUTERNE X, PEYRIN-BIROULET L, HAUSFATER P.

    Digestive and Liver Disease ; 2019